insights_auto
Pse është rritur AXGN 2,61%?
Zhytu më thellëchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
50,02 US$
arrow_upward
+2,61%(+1,27) 1D
50,00 US$
arrow_downward
-0,04% (-0,020)bedtimeJashtë orarit
Mbyllur: 6 nën, 4:00:01 m.d., GMT-5 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për AXGN...
Hap
48,55 US$
I lartë
50,29 US$
I ulët
48,14 US$
Kapitalizimi i tregut
2,99 mld
Vëllimi mesatar
1,79 mln
Vëllimi
1,67 mln
Maksimumi 52-javor
52,91 US$
Minimumi 52-javor
23,00 US$
Fitimet për aksion
-0,68 US$
Beta
1,21
Aksionet në qarkullim
59,73 mln
Numri i punonjësve
622
Hap
48,55 US$
I lartë
50,29 US$
I ulët
48,14 US$
Kapitalizimi i tregut
2,99 mld
Vëllimi mesatar
1,79 mln
Vëllimi
1,67 mln
Maksimumi 52-javor
52,91 US$
Minimumi 52-javor
23,00 US$
Fitimet për aksion
-0,68 US$
Beta
1,21
Aksionet në qarkullim
59,73 mln
Numri i punonjësve
622
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
TradingView
·
46 minuta më parë
News by CNBC TV18 on TradingView, 2026-11-09 — cnbctv:aaec5c086094b:0
Foreign Policy Journal
·
25 minuta më parë
Super Micro Computer (NASDAQ: SMCI) Stock Trades At 8x Forward Earnings Despite Near-Doubling Of Revenue, Attracting 23 Billionaire Investors
Coinpaper
·
37 minuta më parë
S&P 500 Earnings Beats Shrink to Just 2.7%, Weakest in Four Years Despite 84% of Companies Topping Forecasts
Yahoo Finance
·
1 orë më parë
Forget the High-Beta Hype: 5 ‘Sleep Well at Night’ Stocks to Buy Now
Profili
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Rreth AxoGen, Inc Common Stock
Drejtori ekzekutiv-
Punonjësit622
Themeluar më2002
SeliaAlachua, Florida, Shtetet e Bashkuara të Amerikës
SektoriHealth Care
IndustriaMedical device
Uebsajtiaxogeninc.com